Stockreport

BioMarin to acquire rare disease drug developer Amicus for $4.8B [Seeking Alpha]

BioMarin Pharmaceutical Inc.  (BMRN) 
Last biomarin pharmaceutical inc. earnings: 4/29 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.biomarin.com
PDF As part of the transaction, San Rafael, California-based BioMarin ( BMRN ) will offer $14.50 per Newsletters for Every Investor Get daily, sector-specific newslette [Read more]